9/28/20: Announcing our 12th profile from Australia

The Victorian Cancer Registry was established in 1939.  This Registry is the longest running comprehensive cancer registry in Australia and among the oldest continuously operating registries in the world. Currently, about 240 hospitals and 30 pathology laboratories notify the Registry of cancer cases. The Registry folks can work with researchers to recruit patients with cancer for research projects. They support research which fosters improvements and innovations in cancer prevention, clinical practice and cancer service delivery.

Victorian Cancer Registry (Australia)

Database Contact Data

Professor Sue Evans
Director, Victorian Cancer Registry
200 Victoria Parade
East Melbourne VIC 3002
AUSTRALIA
Email: sue.evans@cancervic.org.au
Phone: +61(0) 3 9514 6236
Fax: +61 (0) 3 9514 6751

Alternate Contact

Dr. Catherine Shang
Deputy Director, Victorian Cancer Registry
200 Victoria Parade
East Melbourne VIC 3002
AUSTRALIA
Email: catherine.shang@cancervic.org.au
Phone: +61(0) 3 9514 6236
Fax: +61(0) 3 9514 6751

General Enquiries:
Email: vcr@cancervic.org.au
Phone: +61(0) 3 9514 6236
Fax: +61(0) 3 9514 6751
Mail: 200 Victoria Parade, East Melbourne VIC 3002, AUSTRALIA

References of Studies Using/Describing Database

1. Afshar N, Dashti SG, Mar V, Te Marvelde L, Evans S, Milne RL, English DR. Do age at diagnosis, tumour thickness and tumour site explain sex differences in melanoma survival? A causal mediation analysis using cancer registry data. Int J Cancer. 2024 Mar 1;154(5):793-800.  

2. McPhail S, Barclay ME, Johnson SA, Swann R, Alvi R, Barisic A, Bucher O, Creighton N, Denny CA, Dewar RA, Donnelly DW, Dowden JJ, Downie L, Finn N, Gavin AT, Habbous S, Huws DW, May L, McClure CA, Møller B, Musto G, Nilssen Y, Saint-Jacques N, Sarker S, Shack L, Tian X, Thomas RJS, Thomson CS, Wang H, Woods RR, You H, Lyratzopoulos G; ICBP Module 9 Chemotherapy Group. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study. Lancet Oncol. 2024 Mar;25(3):338-351.  

3. Gao L, Ugalde A, Livingston PM, White V, Watts JJ, Jongebloed H, McCaffrey N, Menzies D, Robinson S. Simulating the healthcare workforce impact and capacity for pancreatic cancer care in Victoria: a model-based analysis. BMC Health Serv Res. 2024 Feb 23;24(1):239.

4. Evans SM, Ivanova K, Cossio D, Pilgrim CHC, Croagh D, Zalcberg J, Giffard D, Golobic N, Di Muzio B, McLean C C, McLean K, Miller GC, Nicosia S, O'Rourke N, Parikh S, Standish R, Te Marvelde L. Registry-derived stage (RD-Stage) for capturing stage at diagnosis for pancreatic carcinoma in Australia. PLoS One. 2024 Jan 2;19(1):e0294443.

5. Pilgrim CHC, Finn N, Stuart E, Philip J, Steel S, Croagh D, Lee B, Tebbutt NC. Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit. ANZ J Surg. 2023 Nov;93(11):2638-2647.

6. Sung N, Muthusamy A, Finn N, Stuart E, Fox J, Yeo B. Surgical management of breast cancer in Victoria: A state-wide audit. Asia Pac J Clin Oncol. 2023 Aug;19(4):499-506.

7. Kang TMJ, Ratnayake G, Wada M, Phillips C, Ruben J, Senthi S, Foroudi F, Millar J, Ong WL. Real-world data on patterns and outcomes of radiation therapy for brain metastases in a population-based cohort of lung cancer patients in Victoria. J Med Imaging Radiat Oncol. 2023 Aug;67(5):546-555.

8. Stuart GW, Chamberlain JA, Te Marvelde L. The contribution of prognostic factors to socio-demographic inequalities in breast cancer survival in Victoria, Australia. Cancer Med. 2023 Jul;12(14):15371-15383.

9. Lindström S, Wang L, Feng H, Majumdar A, Huo S, Macdonald J, Harrison T, Turman C, Chen H, Mancuso N, Bammler T. Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions. JNCI: Journal of the National Cancer Institute. 2023 Jun 1;115(6):712-32.

10. Mnatzaganian G, MacLachlan JH, Allard N, Brown C, Rowe S, Cowie BC. Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma. J Gastroenterol Hepatol. 2023 Jun;38(6):976-983.

9/25/20: Finally we have our 325th profile...

The COTA database is sourced from electronic health records (EHR) of contributing academic, for-profit, and community oncologist provider sites and hospital systems. COTA contains detailed demographic, diagnostic, molecular and genomic testing, treatment, and outcome data. As of June 2020, COTA’s database is a geographically and genetically diverse set, comprised of rich longitudinal patient records collected from >40 unique locations across North America.

COTA (USA)

Database Contact Data

Email: info@cotahealthcare.com

Alternate Contact

If you cannot reach the database manager, please try completing the contact form at:
https://cotahealthcare.com/contact/

References of Studies Using/Describing Database

1. Hoff FW, Patel PA, Belli AJ, Hansen E, Foss H, Schulte M, Wang CK, Madanat YF. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. Leuk Lymphoma. 2023 Apr 13:1-6.

2. Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Stenzinger A, Thomas M. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC. J Thorac Oncol. 2023 Feb 3:S1556-0864(23)00095-3.

3. Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer. 2022 Jun;168:74-82. 

4. Hamadani M, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):373-381.

5. Kushi LH, Lasiter L, Belli AJ, et al. Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data. Journal of Clinical Oncology 2020;38:e19311-e.

6. Rivera DRR, Lasiter L, Christian J, et al. Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration. Journal of Clinical Oncology 2020;38:e19270-e.

7. Mathura S, Fung VK, Dilwali K, Lakshmanan AS. Incorporating molecular markers in standard prognostic models for DLBCL patients using real-world data. Journal of Clinical Oncology 2020;38:e19251-e.

8. Mathura S, Lane D, Hansen E, et al. Disparities in clinical characteristics and treatment of multiple myeloma in African American patients. Journal of Clinical Oncology 2020;38:e19008-e.

9. Lane D, Norden AD, Belli AJ, Wang C-K. Assessing real-world clinical response in patients with multiple myeloma (MM): A survey of the literature. Journal of Clinical Oncology 2020;38:e19260-e.

10. Gutierrez ME, Price KS, Lanman RB, et al. Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. JCO Precision Oncology 2019:1-9.

Subscribe to